Education
About Us
Working with TipRanks
Follow Us
InMed Pharmaceuticals (DE:MWG)
FRANKFURT:MWG
MWG Stock Chart & Stats
€0.85
-€0.14(-2.97%)
At close: 4:00 PM EST
€0.85
-€0.14(-2.97%)
Day’s Range― - ―
52-Week Range€0.67 - €6.60
Previous CloseN/A
Volume0.00
Average Volume (3M)50.00
Market Cap
€2.13M
Enterprise Value-€7.26M
Total Cash (Recent Filing)€9.60M
Total Debt (Recent Filing)€730.14K
Price to Earnings (P/E)―
Beta3.21
Next Earnings
May 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.44
Shares Outstanding2,919,186
10 Day Avg. Volume150
30 Day Avg. Volume50
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.24
Price to Sales (P/S)0.64
P/FCF Ratio-0.41
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Balance SheetVery low reported leverage and consistently positive equity reduce bankruptcy and interest-rate risk, giving management structural flexibility to fund R&D via equity or partnerships rather than expensive debt. This durable balance-sheet positioning supports long-term program investment and strategic options.
Revenue Growth And Improving Gross MarginMulti-year top-line growth with material margin improvement signals early commercial or operational progress in manufacturing or product mix. Sustained revenue expansion and higher gross margins reduce future funding needs and make scaling clinical programs and partnerships more feasible over the medium term.
Clinical Pipeline De-risking (INM-901, INM-089)Robust PK in large animals and active pre-IND/preclinical progress materially lower technical risk for key programs. Advancement toward human trials and GLP-enabling work increases prospects for partnering, milestone payments or IND filings, underpinning long-term value creation beyond current lab-stage status.
Bears Say
Persistent Negative Cash FlowChronic operating and free-cash-flow deficits create ongoing reliance on external financing and raise dilution risk for shareholders. Large, volatile cash burn limits runway, stresses capital-allocation choices, and forces frequent equity raises unless commercial cash generation or partner funding is secured.
Large Operating And Net LossesOperating and net losses far exceed revenues, indicating the cost structure is distant from breakeven. Sustained negative profitability reduces returns on invested capital and requires repeated financing or strategic exits; it also constrains investment pace in development without diluting stakeholders.
Regulatory Risk To BayMedica BusinessLegislative action that threatens a subsidiary's commercial model is a structural business risk: loss of BayMedica revenue and potential asset impairments would reduce diversification, cut near-term cash contributions, and increase strategic uncertainty for a company already dependent on external funding.
InMed Pharmaceuticals News
MWG FAQ
What was InMed Pharmaceuticals’s price range in the past 12 months?
InMed Pharmaceuticals lowest stock price was €0.67 and its highest was €6.60 in the past 12 months.
What is InMed Pharmaceuticals’s market cap?
InMed Pharmaceuticals’s market cap is €2.13M.
When is InMed Pharmaceuticals’s upcoming earnings report date?
InMed Pharmaceuticals’s upcoming earnings report date is May 18, 2026 which is in 86 days.
How were InMed Pharmaceuticals’s earnings last quarter?
InMed Pharmaceuticals released its earnings results on Feb 11, 2026. The company reported -€0.436 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.436.
Is InMed Pharmaceuticals overvalued?
According to Wall Street analysts InMed Pharmaceuticals’s price is currently Overvalued.
Does InMed Pharmaceuticals pay dividends?
InMed Pharmaceuticals does not currently pay dividends.
What is InMed Pharmaceuticals’s EPS estimate?
InMed Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does InMed Pharmaceuticals have?
InMed Pharmaceuticals has 2,919,186 shares outstanding.
What happened to InMed Pharmaceuticals’s price movement after its last earnings report?
InMed Pharmaceuticals reported an EPS of -€0.436 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -14.013%.
Which hedge fund is a major shareholder of InMed Pharmaceuticals?
Currently, no hedge funds are holding shares in DE:MWG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
InMed Pharmaceuticals
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies; and IntegraSyn, an integrated biosynthesis-based manufacturing approach, for synthesizing pharmaceutical-grade cannabinoids. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.
Technical Analysis
Alaunos Therapeutics
―
―
Xenetic Biosciences
―
Ensysce Biosciences
―
Pasithea Therapeutics Corp
―
Options Prices
Currently, No data available
---